Pharmacogivilance consists in carefully monitoring drugs in order to re-evaluate their risk for people’s health. The sooner the Adverse Drug Reactions are detected, the sooner one can act consequently. This thesis aims at discovering such reactions in electronical health records under the constraint of lacking annotated data, in order to replicate the scenario of the Regional Center for Pharmacovigilance of Nice. We investigate how in a semi-supervised learning design the unlabeled data can contribute to improve classification scores. Results suggest an excellent recall in discovering adverse reactions and possible classification improvements under specific data distribution. / Läkemedelsövervakningen består i kolla försiktigt läkemedlen så att utvärdera dem för samhällets hälsa. Ju tidigare de läkemedelsrelaterade biverkningarna upptäcks, desto tidigare man får handla dem. Detta exjobb söker att upptäcka de där läkemedelsrelaterade biverkningarnna inom elektroniska hälsopost med få datamärkningar, för att återskapa Nice regionalt läkemedelelsöveraknings-centrumets situationen. Vi undersöker hur en halvväglett lärande lösning kan hjälpa att förbättra klassificeringsresultat. Resultaten visar en god återställning med biverknings-upptäckning och möjliga förbättringar.

No / AIMS: The aims of this study were to determine the recording of drug sensitivities of elderly care home residents, to describe the nature of sensitivities and to identify and describe discrepancies in the documentation of drug sensitivity status in general practices, pharmacies and care homes. METHODS: A random sample of residents within a purposive sample of care homes (nursing and residential) was selected. A clinical pharmacist inspected the GP medical record, the medicines administration record, and the care home record for each resident to identify drug sensitivities and discrepancies between records and to describe the nature of the recorded sensitivities. RESULTS: The records of 121 residents in 31 care homes were studied. Thirty-one (26%) residents had at least one documented drug sensitivity in one of the sources inspected, with 48 sensitivities in total recorded. There was no description of the nature of the sensitivities recorded in 39/48 (81%) cases. The number of sensitivities recorded on the medicines administration record, care home record and the GP record were 3 (6%), 29 (60%) and 35 (73%), respectively. Only two sensitivities were simultaneously recorded on all three records. CONCLUSIONS: It was of concern that over 90% of drug sensitivities were not recorded on the medicines administration record which is the final checking document when administering medication. The reason for this was that the dispensing pharmacy was responsible for generating the medicines administration record; however, drug sensitivity status is seldom shared between the GP and the dispensing pharmacy. Printing sensitivities on prescriptions would help to resolve this.

Les patients admis aux soins intensifs (SI) souffrent de comorbidités qui affectent leur pronostic. Deux problèmes sont potentiellement associés aux sédatifs et compliquent le séjour de 35 à 50% des malades : le délirium, un état confusionnel aigu; et le coma ‘iatrogénique’, une altération de la conscience induite pharmacologiquement. L’importance de l’association entre clinique et médicaments a un intérêt pour prévenir ces syndromes cliniques morbides. Nous voulions étudier le délirium et le coma iatrogénique, les doses administrées de midazolam et de fentanyl, leurs niveaux plasmatiques, les variantes génétiques de métabolisme et de transport et les facteurs inflammatoires et ce, chez 100 patients admis aux soins intensifs. Nos données soulignent l’importance des interactions médicamenteuses dans l’incidence du coma iatrogénique, et réfutent l’association entre les benzodiazépines et le délirium. Ces résultats clarifient la pathophysiologie du délirium, corroborent le manque d’association délirium-benzodiazépines avec un marqueur biologique, c.-à-d. les niveaux sériques, et ouvrent le débat quant aux agents les plus utiles pour traiter l’anxiété et le délirium. Finalement, plusieurs caractéristiques pharmacocinétiques des benzodiazépines administrées aux soins intensifs publiées récemment complètent les données de notre étude quant à la sédation en soins critiques. Un chapitre sur l’importance de la pharmacogénomique en soins intensifs et un débat publié quant au pro et con de l'utilisation des benzodiazépines aux SI, sont soumis en complément de l’étude clinique décrite ci-haut effectuée dans le cadre de cette maîtrise. / Critically ill patients suffer from co-morbid conditions that impact on their prognosis. Two problems complicate Intensive Care Unit (ICU) stay in 35-50% of patients and are potentially associated with sedatives: delirium, an acute confusional state, and 'iatrogenic' coma, when consciousness is altered pharmacologically. Establishing the association between these clinical syndromes and administering sedatives is key in planning effective prevention of these morbid complications. We studied iatrogenic delirium and coma in 100 ICU patients given midazolam and/or fentanyl, and tallied drug doses, measured plasma levels, genetic variations in metabolism and transport and inflammatory factors. Our data highlight the role drug-drug interactions play in iatrogenic coma, and refute the association between benzodiazepines and delirium. These results clarify the pathophysiology of delirium, corroborate the lack of delirium-benzodiazepine association with a benzodiazepine biological marker, i.e. serum levels, and open the debate as to which agents are useful for treating anxiety and delirium. Recent publications addressing benzodiazepine pharmacokinetics in critical care complement our data in the field of critical care sedation. A chapter on the importance of pharmacogenomics in intensive care, and a published pro-con debate as to benzodiazepine use in critical care are submitted in addition to the clinical study mentioned above as part of this master’s thesis.

Background: In paediatrics, the limited documentation to guide medication, the lack of suitable dosage forms, and the continuous development in childhood present a scenario where safety of medication is a particular challenge. Aim: To explore reported adverse drug reactions (ADRs) and the challenges in prescribing and administering medicines in paediatrics, in order to identify and suggest areas needing international surveillance within medication safety and improvement in the clinical setting. Methods: Four exploratory studies were conducted. Worldwide reporting of suspected ADRs (individual case safety reports, ICSR) with ages 0-17 years were examined overall. Twenty published case reports and ICSRs for adolescents, who developed a rare and incompletely documented ADR (rhabdomyolysis) during antipsychotic medicine use, were analysed in-depth. Prescribed doses of anti-inflammatory medicines were studied in a UK electronic health record database. Transcribed focus group interviews with 20 registered nurses from four paediatric wards in Sweden were analysed for factors that may promote or hinder safe medication practices. Descriptive statistics, multiple regression, and content analyses were used. Results: Although, skin reactions and anti-infective medicines were most frequently reported, and more reported in paediatric patients than in adults, medication errors and adverse reactions related to psychostimulant medicines were reported with increased frequency during 2005 to February 2010. The in-depth case analysis emphasised the need for increased vigilance following changes in patients’ medicine regimens, and indicated that ICSRs could contribute with clinically valuable information. Prescribed dose variations were associated with type of dosage form. Tablets and capsules were prescribed with a higher dose than liquid dosage forms. Six themes emerged from the interviews: preparation and administration was complex; medication errors caused considerable psychological burden; support from nurse colleagues was highly valued; unfamiliar medication was challenging; clear dose instructions were important; nurses handling medications needed to be accorded higher priority. Conclusions: Age-specific screening of ICSRs and the use of ICSRs to enhance knowledge of ADRs and medication errors need to be developed. Access to age-appropriate dosage forms is important when prescribing medicines to children. To improve medication safety practices in paediatric care, interdisciplinary collaborations across hospitals on national or even global levels are needed.

Structured Product Labels (SPLs), the package inserts that accompany drugs governed by the Food and Drugs Administration (FDA), hold information about Adverse Drug Reactions (ADRs) that exists associated with drugs post-market. This information is valuable for actors working in the field of pharmacovigilance aiming to improve the safety of drugs. One such actor is Uppsala Monitoring Centre (UMC), a non-profit conducting pharmacovigilance research. In order to access the valuable information of the package inserts, UMC have constructed an SPL mining pipeline in order to mine SPLs for ADRs. This project aims to investigate new approaches to the solution to the Scan problem, the part of the pipeline responsible for extracting mentions of ADRs. The Scan problem is solved by approaching the problem as a Named Entity Recognition task, a subtask of Natural Language Processing. By using the transformer-based deep learning model BERT, with domain-specific pre-training, an F1-score of 0.8220 was achieved. Furthermore, the chosen model was used in an iteration of Active Learning in order to efficiently extend the available data pool with the most informative examples. Active Learning improved the F1-score to 0.8337. However, the Active Learning was benchmarked against a data set extended with random examples, showing similar improved scores, therefore this application of Active Learning could not be determined to be effective in this project.